Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2023）
摘要
BV-AVD demonstrated an improvement in the PET-negative rate compared with ABVD after two cycles.
更多查看译文
关键词
lymphoma,first-line,early-stage,open-label
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要